What is Sales and Marketing Strategy of Eurofins Scientific Company?

Dedicated global account teams sell multi-year, multi-country testing frameworks to pharma/biotech, food & beverage multinationals, CROs and government buyers; in 2024 over 60% of revenue derived from recurring B2B contracts with pricing indexed to volume and SLAs.

eLIMS, client portals and API integrations with client LIMS/ELNs enable online ordering, sample tracking and data delivery; digital order intake grew to an estimated 35–40% of routine testing volumes in 2024, up from ~20% in 2019.

Local sales and application scientists prospect midsize manufacturers and municipalities and support method selection/validation in ISO/GLP/GMP environments, a key lever for pharma QC and release testing.

Centralized bid teams manage framework agreements for public health, water and environmental monitoring; tender-driven revenues spiked during 2020–2022 and normalized by 2024 while preferred-supplier status in multiple EU and US states preserved pipeline visibility.

Collaborations with instrument vendors and kit distributors, plus white-label retail and DTC arrangements, expanded sample inflows—notably in consumer genomics and food authenticity—without heavy consumer marketing spend.

Shifted from lab-by-lab selling (1990s–2000s) to coordinated key-account and omnichannel models in the 2010s; post-2020 acceleration of digital onboarding and remote audits. DTC testing was deemphasized after 2022 in favor of regulated B2B where renewal rates exceed 90% and average contract values rose mid-single digits in 2024.

Marketed as 'Testing for Life', the brand foregrounds compliance leadership (GMP/GLP/ISO) and end-to-end services from method development to routine QC, targeting technical buyers and procurement.

Clinical, data-forward visual identity (clean blues/greens, laboratory imagery) with a precise, expert tone aimed at QA heads and regulatory affairs professionals.

Innovation at scale with 200,000+ methods and multiple centers of excellence; speed and TAT reliability; regulatory fluency across regions; sustainability stewardship in food authenticity, PFAS and microplastics testing.

For QA heads, regulatory affairs, procurement and R&D, the brand promises reduced compliance risk and faster time-to-market, with services routinely cited on supplier scorecards.

Objective: rapid scale-up of diagnostic capacity and genome surveillance; creative: 'Testing for Life' urgency messaging with government and corporate readiness; channels: government tenders, enterprise outreach, PR, dedicated microsites; results: billions of euros in cumulative COVID-related revenues at peak and millions of tests processed, accelerating public-sector relationships and commercial onboarding.

Objective: position as go-to partner as EU/US rules tightened; creative: 'From ppt to policy' content hub with method explainers; channels: SEO/SEM, LinkedIn ABM, webinars, trade press; results: double-digit growth in environmental testing inquiries and multi-year contracts with utilities and industrials.

Objective: win complex biologics and CGT quality programs; creative: centres-of-excellence storytelling, TAT/quality KPIs, virtual lab tours; channels: CPHI/BIO, targeted email nurtures, sales-engineering workshops; results: incremental wins with top-20 pharma sponsors and higher average contract values.

Objective: consolidate preferred-supplier status with retailers and F&B brands; creative: 'Trust through transparency' audits and dashboard reporting; channels: retailer partnerships, white-label programs, co-branded safety campaigns; results: exclusive frameworks in multiple markets and sustained sample volume growth.

Objective: sustain brand equity and talent pipeline post-peak pandemic; creative: employee-scientist storytelling and sustainability commitments; channels: LinkedIn, university partnerships, PR; results: improved applicant flows and client perception on innovation and reliability.

Approach combined regulatory-timed ABM, technical content, and logistics integration to shorten sales cycles; commercial outcomes included multi-year environmental and pharma contracts and higher client LTV across segments.